Clinical Trials

Study Title:
An Open Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein Barr Virus Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL 1)

For more information about the trial above please contact the study team:

Principal Investigator, Irl Greenwell, at greenwe@musc.edu, or please call +1 843-792-4759.

Study Coordinator, Sarah Milligan, at millisar@musc.edu.

Trial opened at the following institutions: Medical University of South Carolina